Mp09-05 Does the New Prostate Cancer Grading System Improve Prediction of Clinical Recurrence?
Year: 2016
Type: article
Study design: Observational Study
Abstract: METHODS: We utilized a national cohort of 231,174 veterans between the ages of 40 and 70 years, free of heart disease, who at least annually visited the Veterans Healthcare Administration (VHA), who underwent PSA screening between October 2000 and September 2007.We identified 2805 patients (1044 AAV, 1761 WV) who were diagnosed with PCa.Kaplan-Meier and Cox proportional hazards analyses were performed for overall (OS) and cancer-specific survival (CSS).Comorbidity was measured by Charlson comorbidity index.P-value of <0.05 was considered statistically significant.RESULTS: At median follow-up of 87 months, OS was significantly different between the groups (90% for WV and 82% for AAV, logrank p < 0.0001) (Figure 1a).CSS was also significantly different between the groups (98% for WV and 97% for AAV, log-rank p ¼ 0.012) (Figure 1b).When controlling for age, PSA, treatment, Gleason score, and comorbidity, race was an independent and significant predictor of all-cause mortality (HR 1.8, CI 1.4 to 2.2) and PCa-specific mortality (HR¼1.9,CI 1.1 to 3.1).CONCLUSIONS: In a population of regular users of the VHA diagnosed with PCa, we found significant differences in both OS and CSS based on race.In an equal access healthcare environment, when controlling for patient and tumor factors, as well as treatment received, race remained an independent predictor of OS and CSS, which suggests that disparities in PCa outcomes are in part due to inherent differences in PCa biology between races.
Source: The Journal of Urology
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2333939892